LABRIE, FERNAND / Medicine / Researchers

International Center for Scientific Research

Researchers

Medicine / LABRIE, FERNAND

Fernand.Labriephs.ulaval.ca

Position

Directeur du Centre de recherche du Centre hospitalier de l\'Université Laval (CHUL), Université Laval, Canada.

Research interests

En se servant de la souris comme modèle, le Dr Labrie dirige un projet de génomique à grande échelle visant à isoler l\'ensemble des gènes et des protéines contrôlés par cinq catégories de stéroïdes. Le Dr Labrie est un chef de fil mondial dans le domaine de l\'endocrinologie moléculaire au Centre hospitalier de l\"université de Laval (CHUL) et à l\'Université Laval. Ce projet, l\'Atlas des profils génomiques de l\'action stéroïde, vise à déterminer en quoi la recherche en génomique portant sur une espèce, en l\'occurrence la souris, peut s\'appliquer à une autre espèce, l\'humain.

Le Dr Fernand Labrie est considéré comme l\'un des chefs de file mondiaux en matière d\'identification et de clonage moléculaire des enzymes associées à la synthèse des hormones stéroïdes sexuelles.

Des nombreuses contributions du Dr Labrie, une des plus importantes a mené à la mise au point du traitement du cancer de la prostate. Le Dr Labrie et son équipe ont également mis au point une technique de dépistage précoce du cancer, ce qui accroît sensiblement les chances de survie d\'un patient.

Prizes and awards

Le Dr Labrie s\'est vu décerner de nombreux prix et mentions. On lui a décerné le Prix du gouverneur général du Canada en 1967 et la Médaille du Collège de France en 1984. Il est membre de l\'Ordre du Canada, de l\'Ordre national du Québec et un fellow de la Société royale du Canada.

Publications

Levesque MH, El-Alfy M, Berger L, Labrie F, Labrie C. Evaluation of AIbZIP and Cdc47 as markers for human prostatic diseases. Urology. (2007) 69 : 196-201 .

Azzi L, El-Alfy M, Labrie F. Gender differences and effects of sex steroids and dehydroepiandrosterone on androgen and oestrogen alpha receptors in mouse sebaceous glands. Br J Dermatol. (2006) 154 : 21-7 .

Candas B, Labrie F, Gomez JL, Cusan L, Chevrette E, Lévesque J, Brousseau G. Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits. J Urol. (2006) 175 : 510-6; discussion 516-7 .

Yoshioka M, Boivin A, Ye P, Labrie F, St-Amand J. Effects of dihydrotestosterone on skeletal muscle transcriptome in mice measured by serial analysis of gene expression. J Mol Endocrinol. (2006) 36 : 247-59 .

Labrie F, Bélanger A, Bélanger P, Bérubé R, Martel C, Cusan L, Gomez J, Candas B, Castiel I, Chaussade V, Deloche C, Leclaire J. Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women. J Steroid Biochem Mol Biol. (2006) 99 : 182-8 .

Lemieux C, Gélinas Y, Lalonde J, Labrie F, Richard D, Deshaies Y. Hypocholesterolemic action of the selective estrogen receptor modulator acolbifene in intact and ovariectomized rats with diet-induced hypercholesterolemia. Metabolism. (2006) 55 : 605-13 .

Pereira de Jésus-Tran K, Côté PL, Cantin L, Blanchet J, Labrie F, Breton R. Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Sci. (2006) 15 : 987-99 .

Takase Y, Lévesque MH, Luu-The V, El-Alfy M, Labrie F, Pelletier G. Expression of enzymes involved in estrogen metabolism in human prostate. J Histochem Cytochem. (2006) 54 : 911-21 .

Labrie F. Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA. Endocr Relat Cancer. (2006) 13 : 335-55 .

Labrie F, Luu-The V, Martel C, Chernomoretz A, Calvo E, Morissette J, Labrie C. Dehydroepiandrosterone (DHEA) is an anabolic steroid like dihydrotestosterone (DHT), the most potent natural androgen, and tetrahydrogestrinone (THG). J Steroid Biochem Mol Biol. (2006) 100 : 52-8 .

Labrie F. Dehydroepiandrosterone, androgens and the mammary gland. Gynecol Endocrinol. (2006) 22 : 118-30 .

Eriksson AL, Lorentzon M, Mellström D, Vandenput L, Swanson C, Andersson N, Hammond GL, Jakobsson J, Rane A, Orwoll ES, Ljunggren O, Johnell O, Labrie F, Windahl SH, Ohlsson C. SHBG gene promoter polymorphisms in men are associated with serum sex hormone-binding globulin, androgen and androgen metabolite levels, and hip bone mineral density. J Clin Endocrinol Metab. (2006) 91 : 5029-37 .

Song D, Liu G, Luu-The V, Zhao D, Wang L, Zhang H, Xueling G, Li S, Désy L, Labrie F, Pelletier G. Expression of aromatase and 17beta-hydroxysteroid dehydrogenase types 1, 7 and 12 in breast cancer An immunocytochemical study. J Steroid Biochem Mol Biol. (2006) 101 : 136-44 .

Compère V, Ouellet J, Luu-The V, Dureuil B, Tonon MC, Vaudry H, Labrie F, Pelletier G. Role of androgens and glucocorticoids in the regulation of diazepam-binding inhibitor mRNA levels in male mouse hypothalamus. Brain Res. (2006) 1119 : 50-7 .

Labrie F. [Keyrole of endocrinology in the victory against prostate cancer]. Bull Cancer. (2006) 93 : 949-58 .

Liby K, Rendi M, Suh N, Royce DB, Risingsong R, Williams CR, Lamph W, Labrie F, Krajewski S, Xu X, Kim H, Brown P, Sporn MB. The Combination of the Rexinoid, LG100268, and a Selective Estrogen Receptor Modulator, Either Arzoxifene or Acolbifene, Synergizes in the Prevention and Treatment of Mammary Tumors in an Estrogen Receptor-Negative Model of Breast Cancer. Clin Cancer Res. (2006) 12 : 5902-9 .

Faucher F, Pereira de Jésus-Tran K, Cantin L, Luu-The V, Labrie F, Breton R. Crystal structures of mouse 17alpha-hydroxysteroid dehydrogenase (apoenzyme and enzyme-NADP(H) binary complex): identification of molecular determinants responsible for the unique 17alpha-reductive activity of this enzyme. J Mol Biol. (2006) 364 : 747-63 .

Azzi L, El-Alfy M, Martel C, Labrie F. Gender differences in mouse skin morphology and specific effects of sex steroids and dehydroepiandrosterone. J Invest Dermatol. (2005) 124 : 22-7 .

Labrie F, Luu-The V, Calvo E, Martel C, Cloutier J, Gauthier S, Belleau P, Morissette J, Lévesque MH, Labrie C. Tetrahydrogestrinone induces a genomic signature typical of a potent anabolic steroid. J Endocrinol. (2005) 184 : 427-33 .

Dinel S, Bolduc C, Belleau P, Boivin A, Yoshioka M, Calvo E, Piedboeuf B, Snyder EE, Labrie F, St-Amand J. Reproducibility, bioinformatic analysis and power of the SAGE method to evaluate changes in transcriptome. Nucleic Acids Res. (2005) 33 : e26 .

Lemieux C, Gélinas Y, Lalonde J, Labrie F,
Cianflone K, Deshaies Y. Hypolipidemic action of the SERM acolbifene is associated with decreased liver MTP and increased SR-BI and LDL receptors. J Lipid Res. (2005) 46 : 1285-94 .

Pelletier G, Luu-The V, Li S, Labrie F. Localization of type 7 17beta-hydroxysteroid dehydrogenase in mouse tissues. In situ hybridization studies. J Steroid Biochem Mol Biol. (2005) 93 : 49-57 .

Maltais R, Mercier C, Labrie F, Poirier D. Solid-phase synthesis of model libraries of 3alpha,17beta-dihydroxy-16alpha-(aminoethyl-N-substituted)-5alpha-androstanes for the development of steroidal therapeutic agents. Mol Divers. (2005) 9 : 67-79 .

Pelletier G, Lihrmann I, Dubessy C, Luu-The V, Vaudry H, Labrie F. Androgenic down-regulation of urotensin II precursor, urotensin II-related peptide precursor and androgen receptor mRNA in the mouse spinal cord. Neuroscience. (2005) 132 : 689-96 .

Pelletier G, Luu-The V, Li S, Labrie F. Localization of type 5 17beta-hydroxysteroid dehydrogenase mRNA in mouse tissues as studied by in situ hybridization. Cell Tissue Res. (2005) 320 : 393-8 .

Luu-The V, Pelletier G, Labrie F. Quantitative appreciation of steroidogenic gene expression in mouse tissues: new roles for type 2 5alpha-reductase, 20alpha-hydroxysteroid dehydrogenase and estrogen sulfotransferase. J Steroid Biochem Mol Biol. (2005) 93 : 269-76 .

Samson M, Labrie F, Luu-The V. Inhibition of human-type 1 3beta-hydroxysteroid deshydrogenase/Delta(5)-Delta(4)-isomerase expression using siRNA. J Steroid Biochem Mol Biol. (2005) 94 : 253-7 .

Labrie F, Bélanger A, Luu-The V, Labrie C, Simard J, Cusan L, Gomez J, Candas B. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev. (2005) 26 : 361-79 .

Soucy G, Boivin G, Labrie F, Rivest S. Estradiol is required for a proper immune response to bacterial and viral pathogens in the female brain. J Immunol. (2005) 174 : 6391-8 .

Pelletier G, Luu-The V, Li S, Labrie F. Localization of type 8 17beta-hydroxysteroid dehydrogenase mRNA in mouse tissues as studied by in situ hybridization. J Histochem Cytochem. (2005) 53 : 1257-71 .

Lemieux C, Phaneuf D, Labrie F, Giguère V, Richard D, Deshaies Y. Estrogen receptor alpha-mediated adiposity-lowering and hypocholesterolemic actions of the selective estrogen receptor modulator acolbifene. Int J Obes (Lond). (2005) 29 : 1236-44 .

Couture JF, de Jésus-Tran KP, Roy AM, Cantin L, Côté PL, Legrand P, Luu-The V, Labrie F, Breton R. Comparison of crystal structures of human type 3 3alpha-hydroxysteroid dehydrogenase reveals an \'induced-fit\' mechanism and a conserved basic motif involved in the binding of androgen. Protein Sci. (2005) 14 : 1485-97 .

Gauthier S, Cloutier J, Dory Yl, Favre A, Mailhot J, Ouellet C, Schwerdtfeger A, Mérand Y, Martel C, Simard J, Labrie F. Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution. J Enzyme Inhib Med Chem. (2005) 20 : 165-77 .

Berger L, El-Alfy M, Martel C, Labrie F. Effects of dehydroepiandrosterone, Premarin and Acolbifene on histomorphology and sex steroid receptors in the rat vagina. J Steroid Biochem Mol Biol. (2005) 96 : 201-15 .

Tchédam Ngatcha B, Luu-The V, Labrie F, Poirier D. Androsterone 3alpha-ether-3beta-substituted and androsterone 3beta-substituted derivatives as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: chemical synthesis and structure-activity relationship. J Med Chem. (2005) 48 : 5257-68 .

Lemieux C, Gélinas Y, Lalonde J, Labrie F, Richard D, Deshaies Y. The selective estrogen receptor modulator acolbifene reduces cholesterolemia independently of its anorectic action in control and cholesterol-fed rats. J Nutr. (2005) 135 : 2225-9 .

Labrie F, Luu-The V, Bélanger A, Lin SX, Simard J, Pelletier G, Labrie C. Is dehydroepiandrosterone a hormone?. J Endocrinol. (2005) 187 : 169-96 .

Chouinard S, Tessier M, Vernouillet G, Gauthier S, Labrie F, Barbier O, Bélanger A. Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue. Mol Pharmacol. (2005) 69 : 908-20 .

Ngatcha BT, Laplante Y, Labrie F, Luu-The V, Poirier D. 3Beta-alkyl-androsterones as inhibitors of type 3 17beta-hydroxysteroid dehydrogenase: inhibitory potency in intact cells, selectivity towards isoforms 1, 2, 5 and 7, binding affinity for steroid receptors, and proliferative/antiproliferative activities on AR+ and ER+ cell lines. Mol Cell Endocrinol. (2005) 248 : 225-32 .

Pelletier G, Luu-The V, Li S, Labrie F. Localization and estrogenic regulation of androgen receptor mRNA expression in the mouse uterus and vagina. J Endocrinol. (2004) 180 : 77-85 .

Labrie F, Champagne P, Labrie C, Roy J, Laverdière J, Provencher L, Potvin M, Drolet Y, Pollak M, Panasci L, L\'Espérance B, Dufresne J, Latreille J, Robert J, Samson B, Jolivet J, Yelle L, Cusan L, Diamond P, Candas B. Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen-resistant breast cancer. J Clin Oncol. (2004) 22 : 864-71 .

Labrie F, Candas B, Cusan L, Gomez JL, Bélanger A, Brousseau G, Chevrette E, Lévesque J. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate. (2004) 59 : 311-8 .

Labrie F. Medical castration with LHRH agonists: 25 years later with major benefits achieved on survival in prostate cancer. J Androl. (2004) 25 : 305-13 .

Leblanc M, Bélanger Mc, Julien P, Tchernof A, Labrie C, Bélanger A, Labrie F. Plasma lipoprotein profile in the male cynomolgus monkey under normal, hypogonadal, and combined androgen blockade conditions. J Clin Endocrinol Metab. (2004) 89 : 1849-57 .

Qiu W, Zhou M, Labrie F, Lin SX. Crystal structures of the multispecific 17beta-hydroxysteroid dehydrogenase type 5: critical androgen regulation in human peripheral tissues. Mol Endocrinol. (2004) 18 : 1798-807 .

Larose M, St-Amand J, Yoshioka M, Belleau P, Morissette J, Labrie C, Raymond V, Labrie F. Transcriptome of mouse uterus by serial analysis of gene expression (SAGE): comparison with skeletal muscle. Mol Reprod Dev. (2004) 68 : 142-8 .

Couture JF, Legrand P, Cantin L, Labrie F, Luu-The V, Breton R. Loop relaxation, a mechanism that explains the reduced specificity of rabbit 20alpha-hydroxysteroid dehydrogenase, a member of the aldo-keto reductase superfamily. J Mol Biol. (2004) 339 : 89-102 .

Pelletier G, Luu-The V, Li S, Labrie F. Localization of 20alpha-hydroxysteroid dehydrogenase mRNA in mouse brain by in situ hybridization. Brain Res Mol Brain Res. (2004) 125 : 143-6 .

Tchernof A, Labrie F. Dehydroepiandrosterone, obesity and cardiovascular disease risk: a review of human studies. Eur J Endocrinol. (2004) 151 : 1-14 .

Dumont M, Frank D, Moisan AM, Tranchant M, Soucy P, Breton R, Labrie F, Tavtigian SV, Simard J. Structure of primate and rodent orthologs of the prostate cancer susceptibility gene ELAC2. Biochim Biophys Acta. (2004) 1679 : 230-47 .

Pelletier G, Luu-The V, Li S, Ouellet J, Labrie F. Cellular localization of mRNA expression of enzymes involved in the formation and inactivation of hormonal steroids in the mouse prostate. J Histochem Cytochem. (2004) 52 : 1351-6 .

Lépine J, Bernard O, Plante M, Têtu B, Pelletier G, Labrie F, Bélanger A, Guillemette C. Specificity and regioselectivity of the conjugation of estradiol, estrone, and their catecholestrogen and methoxyestrogen metabolites by human uridine diphospho-glucuronosyltransferases expressed in endometrium. J Clin Endocrinol Metab. (2004) 89 : 5222-32 .

Bolduc C, Larose M, Yoshioka M, Ye P, Belleau P, Labrie C, Morissette J, Raymond V, Labrie F, St-Amand J. Effects of dihydrotestosterone on adipose tissue measured by serial analysis of gene expression. J Mol Endocrinol. (2004) 33 : 429-44 .

Pelletier G, Luu-The V, Li S, Ren L, Labrie F. Localization of 17beta-hydroxysteroid dehydrogenase type 1 mRNA in mouse tissues. J Mol Endocrinol. (2004) 33 : 459-65 .

Labrie F. Adrenal androgens and intracrinology. Semin Reprod Med. (2004) 22 : 299-309 .

Labrie F, Cusan L, Gomez J, Luu-The V, Candas B, Bélanger A, Labrie C. Major impact of hormonal therapy in localized prostate cancer--death can already be an exception. J Steroid Biochem Mol Biol. (2004) 92 : 327-44 .

Labrie F. Current status of endocrine therapy in localized prostate cancer: cure has become a strong possibility. Int Braz J Urol. (2004) 30 : 3-11 .

Labrie F, Candas, B., Cusan L, Gomez JL, Lévesque J., Chevrette, E., Brousseau, G. Prostate Cancer Screening and Early Treatment: The only possibility for a major impact on survival in prostate cancer. Prostate Cancer: Understanding the pathophysiology and re-designing a therapeuti approach. (2004) 67-78 .

Labrie F. Status of androgen blockade in prosate cancer in 2003. Prostate cancer: understanding the pathophysiology and re-designing a therapeutic approach. (2004) 157-170 .

Simard J, Dumont M, Soucy P, Labrie F, Tavtigian SV. Prostate Cancer Susceptibility Genes. Prostate Cancer: understanding the pathophysiology and re-designing a therapeutic approach. (2004) 1-38 .

Labrie F. Major role of androgen blockade in the success of prostate cancer treatment: cure has become a very good possibility. Prostate Cancer Communication Newsletter. (2004) 20 : 3-11 .

Gutman M, Couillard S, Labrie F, Candas B, Labrie C. Effect of treatment sequence with radiotherapy and the antiestrogen EM 800 on the growth of ZR 75 1 human mammary carcinoma in nude mice. Int J Cancer. (2003) 103 : 268-76 .

Tatchum-Talom R, Martel C, Labrie F, Marette A. Acute vascular effects of the selective estrogen receptor modulator EM-652 (SCH 57068) in the rat mesenteric vascular bed. Cardiovasc Res. (2003) 57 : 535-43 .

Lemieux C, Picard F, Labrie F, Richard D, Deshaies Y. The estrogen antagonist EM-652 and dehydroepiandrosterone prevent diet- and ovariectomy-induced obesity. Obes Res. (2003) 11 : 477-90 .

Mauriège P, Martel C, Langin D, Lacaille M, Després JP, Bélanger A, Labrie F, Deshaies Y. Chronic effects of dehydroepiandrosterone on rat adipose tissue metabolism. Metabolism. (2003) 52 : 264-72 .

Labrie F, Luu-The V, Labrie C, Bélanger A, Simard J, Lin SX, Pelletier G. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev. (2003) 24 : 152-82 .

Jensen J, Kitlen JW, Briand P, Labrie F, Lykkesfeldt AE. Effect of antiestrogens and aromatase inhibitor on basal growth of the human breast cancer cell line MCF-7 in serum-free medium. J Steroid Biochem Mol Biol. (2003) 84 : 469-78 .

Labrie F. Extragonadal synthesis of sex steroids: intracrinology. Ann Endocrinol (Paris). (2003) 64 : 95-107 .

Simard J, Dumont M, Labuda D, Sinnett D, Meloche C, El-Alfy M, Berger L, Lees E, Labrie F, Tavtigian SV. Prostate cancer susceptibility genes: lessons learned and challenges posed. Endocr Relat Cancer. (2003) 10 : 225-59 .

Pelletier G, Li S, Phaneuf D, Martel C, Labrie F. Morphological studies of prolactin-secreting cells in estrogen receptor alpha and estrogen receptor beta knockout mice. Neuroendocrinology. (2003) 77 : 324-33 .

Dimitrakakis C, Zhou J, Wang J, Belanger A, Labrie F, Cheng C, Powell D, Bondy C. A physiologic role for testosterone in limiting estrogenic stimulation of the breast. Menopause. (2003) 10 : 292-8 .

Couture JF, Legrand P, Cantin L, Luu-The V, Labrie F, Breton R. Human 20alpha-hydroxysteroid dehydrogenase: crystallographic and site-directed mutagenesis studies lead to the identification of an alternative binding site for C21-steroids. J Mol Biol. (2003) 331 : 593-604 .

Labrie F, El-Alfy M, Berger L, Labrie C, Martel C, Bélanger A, Candas B, Pelletier G. The combination of a novel selective estrogen receptor modulator with an estrogen protects the mammary gland and uterus in a rodent model: the future of postmenopausal women\'s health?. Endocrinology. (2003) 144 : 4700-6 .

Leblanc M, Labrie C, Bélanger A, Candas B, Labrie F. Bioavailability and pharmacokinetics of dehydroepiandrosterone in the cynomolgus monkey. J Clin Endocrinol Metab. (2003) 88 : 4293-302 .

Ciobanu LC, Luu-The V, Martel C, Labrie F, Poirier D. Inhibition of estrone sulfate-induced uterine growth by potent nonestrogenic steroidal inhibitors of steroid sulfatase. Cancer Res. (2003) 63 : 6442-6 .

Pelletier G, Luu-The V, Li S, Ren L, Labrie F. Sex-related expression of 20alpha-hydroxysteroid dehydrogenase mRNA in the adult mouse. J Histochem Cytochem. (2003) 51 : 1425-36 .

Labrie F, Cusan L, Gomez JL, Candas B, Bélanger A, Luu-The V, Labrie C, Simard J. [From the gene to the clinic: prostate cancer death can now be an exception?]. Med Sci (Paris). (2003) 19 : 910-9 .

Roy J, Couillard S, Gutman M, Labrie F. A novel pure SERM achieves complete regression of the majority of human breast cancer tumors in nude mice. Breast Cancer Res Treat. (2003) 81 : 223-9 .

Belanger A, Pelletier G, Labrie F, Barbier O, Chouinard S. Inactivation of androgens by UDP-glucuronosyltransferase enzymes in humans. Trends Endocrinol Metab. (2003) 14 : 473-9 .

Gingras S, Turgeon C, Brochu N, Soucy P, Labrie F, Simard J. Characterization and modulation of sex steroid metabolizing activity in normal human keratinocytes in primary culture and HaCaT cells. J Steroid Biochem Mol Biol. (2003) 87 : 167-79 .

Sullivan DA, Bélanger A, Cermak JM, Bérubé R, Papas AS, Sullivan RM, Yamagami H, Dana MR, Labrie F. Are women with Sjögren\'s syndrome androgen-deficient?. J Rheumatol. (2003) 30 : 2413-9 .

Akaza H, Hirao Y, Labrie F, Soloway MS. [Future prospects for primary hormone therapy in localized and locally advanced prostate cancer]. Hinyokika Kiyo. (2003) 49 : 771-7 .

Gutman M, Couillard S, Roy J, Labrie F, Candas B, Labrie C. Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude mice. Int J Cancer. (2002) 99 : 273-8 .

Bernardi F, Stomati M, Luisi S, Pieri M, Labrie F, Riccardo Genazzani A. Effects of the new generation selective estrogen receptor modulator EM-652 and oral administration of estradiol valerate on circulating, brain, and adrenal beta-endorphin and allopregnanolone levels in intact fertile and ovariectomized rats. Fertil Steril. (2002) 77 : 1018-27 .

Simard J, Dumont M, Soucy P, Labrie F. Perspective: prostate cancer susceptibility genes. Endocrinology. (2002) 143 : 2029-40 .

Simoncini T, Varone G, Fornari L, Mannella P, Luisi M, Labrie F, Genazzani AR. Genomic and nongenomic mechanisms of nitric oxide synthesis induction in human endothelial cells by a fourth-generation selective estrogen receptor modulator. Endocrinology. (2002) 143 : 2052-61 .

Labrie F, Candas B, Gomez JL, Cusan L. Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?. Urology. (2002) 60 : 115-9 .

Leblanc M, Labrie C, Bélanger A, Candas B, Labrie F. Pharmacokinetics of oral dehydroepiandrosterone (DHEA) in the ovariectomised cynomolgus monkey. J Steroid Biochem Mol Biol. (2002) 81 : 159-64 .

Labrie F, Candas B. Interpreting the Quebec prostate cancer study. CMAJ. (2002) 167 : 340 .

Labrie F. Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease. Mol Cell Endocrinol. (2002) 198 : 77-87 .

Labrie F, Bélanger A, Luu-The V, Simard J, Labrie C. DHEA replacement therapy as a source of androgens and estrogens at menopause. Advances in gynecological endocrinology. (2002) 249-258 .

Labrie F, Labrie C, Bélanger A, Simard J. Third- and Fourth- generation SERMs. Contemporary Endocrinology: Selective Estrogen Receptor Modulators: Research and Clinical Applications. (2002) 167-187 .

Sauvé F, McBroom LD, Gallant J, Moraitis AN, Labrie F, Giguère V. CIA, a novel estrogen receptor coactivator with a bifunctional nuclear receptor interacting determinant. Mol Cell Biol. (2001) 21 : 343-53 .

Dufort I, Labrie F, Luu-The V. Human types 1 and 3 3 alpha-hydroxysteroid dehydrogenases: differential lability and tissue distribution. J Clin Endocrinol Metab. (2001) 86 : 841-6 .

Luu-The V, Dufort I, Pelletier G, Labrie F. Type 5 17beta-hydroxysteroid dehydrogenase: its role in the formation of androgens in women. Mol Cell Endocrinol. (2001) 171 : 77-82 .

Pelletier G, Luu-The V, El-Alfy M, Li S, Labrie F. Immunoelectron microscopic localization of 3beta-hydroxysteroid dehydrogenase and type 5 17beta-hydroxysteroid dehydrogenase in the human prostate and mammary gland. J Mol Endocrinol. (2001) 26 : 11-9 .

Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, Dayananth P, Desrochers M, Dumont M, Farnham JM, Frank D, Frye C, Ghaffari S, Gupte JS, Hu R, Iliev D, Janecki T, Kort EN, Laity KE, Leavitt A, Leblanc G, McArthur-Morrison J, Pederson A, Penn B, Peterson KT, Reid JE, Richards S, Schroeder M, Smith R, Snyder SC, Swedlund B, Swensen J, Thomas A, Tranchant M, Woodland AM, Labrie F, Skolnick MH, Neuhausen S, Rommens J, Cannon-Albright LA. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet. (2001) 27 : 172-80 .

Barbier O, Albert C, Martineau I, Vallée M, High K, Labrie F, Hum DW, Labrie C, Bélanger A. Glucuronidation of the nonsteroidal antiestrogen EM-652 (SCH 57068), by human and monkey steroid conjugating UDP-glucuronosyltransferase enzymes. Mol Pharmacol. (2001) 59 : 636-45 .

Zhu DW, Cantin L, Nahoum V, Rehse P, Luu-The V, Labrie F, Breton R, Lin SX. Crystallization and preliminary X-ray crystallographic analysis of the human type 3 3 alpha-hydroxysteroid dehydrogenase at 1.8 A resolution. Acta Crystallogr D Biol Crystallogr. (2001) 57 : 589-91 .

Labrie F, Labrie C, Belanger A, Giguere V, Simard J, Mérand Y, Gauthier S, Luu-The V, Candas B, Martel C, Luo S. Pure selective estrogen receptor modulators, new molecules having absolute cell specificity ranging from pure antiestrogenic to complete estrogen-like activities. Adv Protein Chem. (2001) 56 : 293-368 .

Labrie F, Luu-The V, Labrie C, Simard J. DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Front Neuroendocrinol. (2001) 22 : 185-212 .

Pelletier G, Labrie C, Martel C, Li S, Labrie F. Role of extra-ovarian oestrogens in the regulation of gonadotropin releasing hormone mRNA expression in the rat brain. J Neuroendocrinol. (2001) 13 : 678-82 .

Nahoum V, Gangloff A, Legrand P, Zhu DW, Cantin L, Zhorov BS, Luu-The V, Labrie F, Breton R, Lin SX. Structure of the human 3alpha-hydroxysteroid dehydrogenase type 3 in complex with testosterone and NADP at 1.25-A resolution. J Biol Chem. (2001) 276 : 42091-8 .

Pelletier G, Li S, Luu-The V, Tremblay Y, Bélanger A, Labrie F. Immunoelectron microscopic localization of three key steroidogenic enzymes (cytochrome P450(scc), 3 beta-hydroxysteroid dehydrogenase and cytochrome P450(c17)) in rat adrenal cortex and gonads. J Endocrinol. (2001) 171 : 373-83 .

Couture JF, Cantin L, Legrand P, Luu-The V, Labrie F, Breton R. Expression, crystallization and preliminary X-ray analysis of human and rabbit 20alpha-hydroxysteroid dehydrogenases in complex with NADP(H) and various steroid substrates. Acta Crystallogr D Biol Crystallogr. (2001) 58 : 135-9 .

Pelletier G, El-Alfy M, Labrie C, Martel C, Labrie F. Effect of long-term treatment with the antiestrogen EM-652.HCl on pituitary estrogen receptor alpha and prolactin mRNA expression in intact, ovariectomized and gonadotropin-releasing hormone-treated female rats. Neuroendocrinology. (2001) 74 : 367-74 .

Labrie F, Labrie C, Belanger A, Simard J, Giguère V, Tremblay A, Tremblay G. EM-652 (SCH57068), a pure SERM having complete antiestrogenic activity in the mammary gland and endometrium. J Steroid Biochem Mol Biol. (2001) 79 : 213-25 .

Crawford ED, Miller GJ, Labrie F, Hirano D, Batuello J, Glodé LM. Prostate cancer pathology, screening, and epidemiology. Rev Urol. (2001) 3 Suppl 2 : S2-S10 .

Gomella LG, Labrie F, Gamito EJ, Brawer MK. Prostate cancer: risk assessment and diagnostic approaches. Rev Urol. (2001) 3 Suppl 2 : S31-8 .

Brawer MK, Crawford ED, Labrie F, Mendoza-Valdes A, Miller PD, Petrylak DP. Androgen deprivation and other treatments for advanced prostate cancer. Rev Urol. (2001) 3 Suppl 2 : S59-68 .

Singh SM, Gauthier S, Labrie F. Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr Med Chem. (2000) 7 : 211-47 .

Couillard S, Labrie C, Gauthier S, Merand Y, Singh SM, Candas B, Labrie F. Long-term inhibitory effect of the orally active and pure antiestrogen EM-800 on the growth of human breast cancer xenografts in nude mice. Int J Cancer. (2000) 85 : 424-9 .

Sam K, Labrie F, Poirier D. N-Butyl-N-methyl-11-(3\'-hydroxy-21\', 17\'-carbolactone-19\'-nor-17\'alpha-pregna-1\',3\', 5\'(10\')-trien-7\'alpha-yl)-undecanamide: an inhibitor of type 2 17beta-hydroxysteroid dehydrogenase that does not have oestrogenic or androgenic activity. Eur J Med Chem. (2000) 35 : 217-25 .

Labrie F. Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support. Prostate. (2000) 43 : 215-22 .

Labrie F. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists\' Collaborative Group. Lancet. (2000) 355 : 1491-8 .

Labrie F. Screening and hormonal therapy of localized prostate cancer shows major benefits on survival. Cancer J. (2000) 6 Suppl 2 : S182-7 .

Pelletier G, Labrie C, Labrie F. Localization of oestrogen receptor alpha, oestrogen receptor beta and androgen receptors in the rat reproductive organs. J Endocrinol. (2000) 165 : 359-70 .

Labrie F, Luu-The V, Lin SX, Simard J, Labrie C, El-Alfy M, Pelletier G, Bélanger A. Intracrinology: role of the family of 17 beta-hydroxysteroid dehydrogenases in human physiology and disease. J Mol Endocrinol. (2000) 25 : 1-16 .

Picard F, Deshaies Y, Lalonde J, Samson P, Labrie C, Bélanger A, Labrie F, Richard D. Effects of the estrogen antagonist EM-652.HCl on energy balance and lipid metabolism in ovariectomized rats. Int J Obes Relat Metab Disord. (2000) 24 : 830-40 .

Sourla A, Richard V, Labrie F, Labrie C. Exclusive androgenic effect of dehydroepiandrosterone in sebaceous glands of rat skin. J Endocrinol. (2000) 166 : 455-62 .

Gyomorey S, Gupta S, Lye SJ, Gibb W, Labrie F, Challis JR. Temporal expression of prostaglandin H synthase type 2 (PGHS-2) and P450(C17)in ovine placentomes with the natural onset of labour. Placenta. (2000) 21 : 478-86 .

Candas B, Cusan L, Gomez JL, Diamond P, Suburu RE, Lévesque J, Brousseau G, Bélanger A, Labrie F. Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer. Prostate. (2000) 45 : 19-35 .

Mauriège P, Langin D, Montminy V, Martel C, Després JP, Bélanger A, Labrie F, Deshaies Y. Effect of a long-term percutaneous adrenal steroid treatment on rat adipose tissue metabolism. Int J Obes Relat Metab Disord. (2000) 24 Suppl 2 : S148-50 .

Labrie F, Candas B. Androgen blockade in prostate cancer. Lancet. (2000) 356 : 341-2 .
Martel C, Picard S, Richard V, Bélanger A, Labrie C, Labrie F. Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat. J Steroid Biochem Mol Biol. (2000) 74 : 45-56 .

El-Alfy M, Pelletier G, Hermo LS, Labrie F. Unique features of the basal cells of human prostate epithelium. Microsc Res Tech. (2000) 51 : 436-46 .

Tatchum-Talom R, Martel C, Labrie C, Labrie F, Marette A. Gender differences in hemodynamic responses to endothelin-1. J Cardiovasc Pharmacol. (2000) 36 : S102-4 .

Boivin RP, Luu-The V, Lachance R, Labrie F, Poirier D. Structure-activity relationships of 17alpha-derivatives of estradiol as inhibitors of steroid sulfatase. J Med Chem. (2000) 43 : 4465-78 .

Labrie F, Luu-The V, Lin SX, Simard J, Labrie C. Role of 17 beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends Endocrinol Metab. (2000) 11 : 421-7 .

Labrie F, Luu-The V, Labrie C, Pelletier G, El-Alfy M. Intracrinology and the skin. Horm Res. (2000) 54 : 218-29 .

Singh R, Eeles RA, Durocher F, Simard J, Edwards S, Badzioch M, Kote-Jarai Z, Teare D, Ford D, Dearnaley D, Ardern-Jones A, Murkin A, Dowe A, Shearer R, Kelly J, Labrie F, Easton D, Narod SA, Tonin PN, Foulkes WD. High risk genes predisposing to prostate cancer development-do they exist?. Prostate Cancer Prostatic Dis.
(2000) 3 : 241-247.

Legal notice - Contact

Copyright © 2013 - www.cirs.info - All rights reserved